A piercing, flexible and simple approach to the US safety needle market
This article was originally published in Clinica
Specialized Health Products International (SHPI) is one of the growing number of small product development companies seeking to capitalise on the increasing importance of safety needle products in the US. Imogen Daulby asked the company how it would survive in such a fiercely competitive area.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.